MedTrace Logo

PPI-Rebound-Trial. A Study of the Clinical Relevance of the Acid Rebound Phenomena

NCT00526006 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2007-09-06

No results posted yet for this study

Summary

The acid secretion in the stomach seems to increase after withdrawal of min. 8 wks of treatment with a PPI (protonpump inhibitor) It is unknown if this acid rebound phenomenon is of clinical significance. In a doubleblinded and placebocontrolled study healthy volunteers are randomized to treatment with placebo or PPI + placebo. Gastrointestinal symptoms are scored once a week and.

Conditions

  • Healthy

Interventions

DRUG

esomeprazole

40 mg od for 8 wks

Sponsors & Collaborators

  • Zealand University Hospital

    lead OTHER

Principal Investigators

  • Christina Reimer, MD · University Hospital Køge

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-09-30
Completion
2008-03-31

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00526006 on ClinicalTrials.gov